altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”
![Altamira Therapeutics logo](https://files.capedge.com/424B5/0000950103-18-013783/image_004.jpg)
Company profile
Ticker
CYTO
Exchange
Website
CEO
Thomas Meyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Auris Medical AG, Auris Medical Holding AG, Auris Medical Holding Ltd.
SEC CIK
CYTO stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
16 May 24
20-F/A
2023 FY
Annual report (foreign) (amended)
22 Apr 24
EFFECT
Notice of effectiveness
18 Apr 24
424B4
Prospectus supplement with pricing info
17 Apr 24
6-K
Notice of the Annual General Meeting of Shareholders
16 Apr 24
6-K
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
10 Apr 24
S-8
Registration of securities for employees
10 Apr 24
F-1
Registration statement (foreign)
10 Apr 24
20-F
2023 FY
Annual report (foreign)
10 Apr 24
424B4
Prospectus supplement with pricing info
22 Jan 24
Latest ownership filings
SC 13D/A
Meyer Thomas
13 Mar 24
SC 13D/A
Meyer Thomas
27 Apr 23
SC 13D/A
Meyer Thomas
18 Jan 23
SC 13D/A
Meyer Thomas
13 Sep 22
SC 13D/A
Meyer Thomas
13 May 22
SC 13D/A
Meyer Thomas
21 May 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13D/A
Meyer Thomas
7 Dec 20
SC 13D/A
Meyer Thomas
6 Oct 20
SC 13D/A
Meyer Thomas
20 Aug 20
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
3.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 47.27 mm |
Total shares | 73.74 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Citadel Advisors | 72.93 k | $46.75 mm |
MS Morgan Stanley | 500.00 | $321.00 k |
Group One Trading | 298.00 | $191.00 k |
Cutler | 10.00 | $0.00 |
Stonebridge Capital Advisors | 5.00 | $6.00 k |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
23 May 24
What's Going On With Altamira Therapeutics Stock?
23 May 24
Altamira Therapeutics Announces Publication Of Results From Bentrio Trial In Seasonal Allergic Rhinitis In Peer Reviewed Journal
24 Apr 24
Altamira Therapeutics FY EPS $(16.47) Sales $284.47K Down From $330.37K YoY
10 Apr 24
Earnings Scheduled For April 10, 2024
10 Apr 24
Press releases
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
20 Jun 24
Altamira Therapeutics Provides Business Update
28 May 24
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
24 May 24
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
23 May 24
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
1 May 24